Answers are grounded in this paper and cite their sources.
We sought to determine whether continuing medical education (CME) changes real world selection of preventative migraine therapies (anti-calcitonin gene-receptor peptide receptor (CGRP) monoclonal antibodies (mABs)) as measured by prescription and medical claims data.
No takes yet. Share an insight, caveat, or question.
Lucero et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: